This study tests a personalized immunotherapy called Vigil in 92 women with advanced ovarian cancer who are currently cancer-free after surgery and chemotherapy. The treatment uses the patient's own tumor cells to create a vaccine that trains the immune system to fight any remain…
Phase: PHASE2 • Sponsor: Gradalis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC